Dale E. Shuster

5.5k total citations · 1 hit paper
67 papers, 3.7k citations indexed

About

Dale E. Shuster is a scholar working on Agronomy and Crop Science, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dale E. Shuster has authored 67 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Agronomy and Crop Science, 17 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dale E. Shuster's work include Milk Quality and Mastitis in Dairy Cows (18 papers), Musculoskeletal synovial abnormalities and treatments (12 papers) and Cancer Treatment and Pharmacology (10 papers). Dale E. Shuster is often cited by papers focused on Milk Quality and Mastitis in Dairy Cows (18 papers), Musculoskeletal synovial abnormalities and treatments (12 papers) and Cancer Treatment and Pharmacology (10 papers). Dale E. Shuster collaborates with scholars based in United States, Italy and Germany. Dale E. Shuster's co-authors include Marcus E. Kehrli, Mark R. Ackermann, R.O. Gilbert, Robert J. Harmon, Fang Fang, Mark G. Stevens, Keith B. Glaser, J. Michael McIntosh, William R. Kem and Barbara C. M. Potts and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer.

In The Last Decade

Dale E. Shuster

67 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The odyssey of marine pharmaceuticals: a current pipeline perspective

2010 441 citations Alejandro M. S. Mayer, Keith B. Glaser et al. Trends in Pharmacological Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dale E. Shuster United States	27	1.2k	847	661	541	495	67	3.7k
Jianhua Gong China	33	265 0.2×	682 0.8×	1.7k 2.6×	915 1.7×	250 0.5×	99	4.9k
Peadar Ó Gaora Ireland	34	793 0.7×	193 0.2×	1.3k 2.0×	898 1.7×	976 2.0×	68	4.0k
Shimeru Kamihira Japan	46	1.6k 1.4×	1.0k 1.2×	1.8k 2.8×	3.0k 5.6×	219 0.4×	199	6.2k
Heng Fong Seow Malaysia	34	214 0.2×	482 0.6×	1.2k 1.8×	643 1.2×	234 0.5×	127	3.2k
Benjamin G. Cocks Australia	35	344 0.3×	570 0.7×	870 1.3×	2.6k 4.8×	805 1.6×	75	5.3k
Jinhua Liu China	42	1.9k 1.6×	313 0.4×	1.2k 1.8×	1.2k 2.3×	485 1.0×	202	6.0k
D.A. Todhunter United States	30	2.1k 1.8×	334 0.4×	416 0.6×	673 1.2×	519 1.0×	75	3.6k
Eishi Baba Japan	33	239 0.2×	1.2k 1.4×	806 1.2×	935 1.7×	73 0.1×	194	3.1k
Roslyn A. Kemp New Zealand	28	331 0.3×	483 0.6×	416 0.6×	825 1.5×	791 1.6×	94	2.3k
Ashok Kumar Mohanty India	27	530 0.4×	146 0.2×	1.1k 1.7×	297 0.5×	453 0.9×	164	2.5k

Countries citing papers authored by Dale E. Shuster

Since Specialization

Citations

This map shows the geographic impact of Dale E. Shuster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dale E. Shuster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dale E. Shuster more than expected).

Fields of papers citing papers by Dale E. Shuster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dale E. Shuster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dale E. Shuster. The network helps show where Dale E. Shuster may publish in the future.

Co-authorship network of co-authors of Dale E. Shuster

This figure shows the co-authorship network connecting the top 25 collaborators of Dale E. Shuster. A scholar is included among the top collaborators of Dale E. Shuster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dale E. Shuster. Dale E. Shuster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wagner, Andrew J., William D. Tap, Sebastian Bauer, et al.. (2025). Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. The Oncologist. 30(7). 1 indexed citations

Hong, Ying, Naoyuki Tajima, Kashyap Patel, et al.. (2023). Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development. CPT Pharmacometrics & Systems Pharmacology. 13(1). 23–28. 3 indexed citations

Zahir, Hamim, Ophelia Yin, Ching Hsu, et al.. (2023). Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy. Clinical Pharmacology in Drug Development. 12(5). 475–483. 4 indexed citations

Zahir, Hamim, Jonathan Greenberg, Dale E. Shuster, et al.. (2022). Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects. Clinical Pharmacokinetics. 61(11). 1623–1639. 5 indexed citations

Sande, Michiel A. J. van de, William D. Tap, Heather L. Gelhorn, et al.. (2021). Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Acta Orthopaedica. 92(4). 493–499. 14 indexed citations

Scagliotti, Giorgio V., Dale E. Shuster, С. В. Орлов, et al.. (2017). Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. Journal of Thoracic Oncology. 13(6). 849–854. 37 indexed citations

Spira, Alexander I., Nicholas Iannotti, Michael A. Savin, et al.. (2011). A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(1). 31–38. 26 indexed citations

Mayer, Alejandro M. S., Keith B. Glaser, Carmen Cuevas, et al.. (2010). The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends in Pharmacological Sciences. 31(6). 255–265. 441 indexed citations breakdown →

Goel, Sanjay, Alain C. Mita, Monica Mita, et al.. (2009). A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 15(12). 4207–4212. 121 indexed citations

10.

Tan, Antoinette R., Eric H. Rubin, Dale E. Shuster, et al.. (2009). Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(12). 4213–4219. 116 indexed citations

11.

Erskine, Ronald J., et al.. (1998). Recombinant Bovine Interleukin-2 and Dry Cow Therapy: Efficacy to Cure and Prevent Intramammary Infections, Safety, and Effect on Gestation. Journal of Dairy Science. 81(1). 107–115. 21 indexed citations

12.

Shuster, Dale E., et al.. (1996). Bacterial growth, inflammatory cytokine production, and neutrophil recruitment during coliform mastitis in cows within ten days after calving, compared with cows at midlactation. American Journal of Veterinary Research. 57(11). 1569–1575. 178 indexed citations

13.

Shuster, Dale E., Marcus E. Kehrli, & Craig R. Baumrucker. (1995). Relationship of Inflammatory Cytokines, Growth Hormone, and Insulin-Like Growth Factor-I to Reduced Performance During Infectious Disease. Experimental Biology and Medicine. 210(2). 140–149. 53 indexed citations

14.

Shuster, Dale E., Marcus E. Kehrli, & Mark G. Stevens. (1993). Cytokine production during endotoxin-induced mastitis in lactating dairy cows. American Journal of Veterinary Research. 54(1). 80–85. 133 indexed citations

15.

Gilbert, R.O., et al.. (1993). Clinical manifestations of leukocyte adhesion deficiency in cattle: 14 cases (1977-1991). Journal of the American Veterinary Medical Association. 202(3). 445–449. 36 indexed citations

16.

Kehrli, Marcus E., Mark R. Ackermann, Dale E. Shuster, et al.. (1992). Animal model of human disease: Bovine leukocyte adhesion deficiency: Beta2 Integrin Deficiency in Young Holstein Cattle. American Journal Of Pathology. 140(6). 10 indexed citations

17.

Shuster, Dale E., Brad T. Bosworth, & Marcus E. Kehrli. (1992). Sequence of the bovine CD18-encoding cDNA: comparison with the human and murine glycoproteins. Gene. 114(2). 267–271. 50 indexed citations

18.

Shuster, Dale E. & Robert J. Harmon. (1992). High Cortisol Concentrations and Mediation of the Hypogalactia During Endotoxin-Induced Mastitis. Journal of Dairy Science. 75(3). 739–746. 18 indexed citations

19.

Shuster, Dale E., Robert J. Harmon, Jackson James, & R.W. Hemken. (1991). Endotoxin Mastitis in Cows Milked Four Times Daily. Journal of Dairy Science. 74(5). 1527–1538. 25 indexed citations

20.

Shuster, Dale E., Robert J. Harmon, J.A. Jackson, & R.W. Hemken. (1991). Suppression of Milk Production During Endotoxin-Induced Mastitis. Journal of Dairy Science. 74(11). 3763–3774. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact